These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11975893)

  • 1. [Severe sepsis and septic shock: crossroad between inflammation and coagulation].
    Torrabadella De Reynoso P
    Med Clin (Barc); 2002 Apr; 118(13):517-8. PubMed ID: 11975893
    [No Abstract]   [Full Text] [Related]  

  • 2. [Severe sepsis and septic shock: crossroad between inflammation and coagulation].
    Jiménez Ortiz JL; Labarta Monzón L; Armengol Sáez S
    Med Clin (Barc); 2002 Jan; 118(2):78. PubMed ID: 11809155
    [No Abstract]   [Full Text] [Related]  

  • 3. [Severe sepsis and septic shock: crossroad of inflammation and coagulation].
    Torrabadella de Reynoso P; Salgado Remigio A
    Med Clin (Barc); 2001 Jun; 116(20):782-8. PubMed ID: 11440685
    [No Abstract]   [Full Text] [Related]  

  • 4. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis.
    Zarychanski R; Abou-Setta AM; Kanji S; Turgeon AF; Kumar A; Houston DS; Rimmer E; Houston BL; McIntyre L; Fox-Robichaud AE; Hébert P; Cook DJ; Fergusson DA;
    Crit Care Med; 2015 Mar; 43(3):511-8. PubMed ID: 25493972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombosis prophylaxis in critically ill patients.
    Fries D
    Wien Med Wochenschr; 2011 Feb; 161(3-4):68-72. PubMed ID: 21404142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of anticoagulants in patients with sepsis.
    Langer M; Riccardi F; Piovella F; Klersy C
    JAMA; 2002 Jan 23-30; 287(4):448-9. PubMed ID: 11798358
    [No Abstract]   [Full Text] [Related]  

  • 7. Should all patients with sepsis receive anticoagulation? Yes.
    Meziani F; Gando S; Vincent JL
    Intensive Care Med; 2017 Mar; 43(3):452-454. PubMed ID: 28194512
    [No Abstract]   [Full Text] [Related]  

  • 8. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboelastometry as a supplementary tool for evaluation of hemostasis in severe sepsis and septic shock.
    Andersen MG; Hvas CL; Tønnesen E; Hvas AM
    Acta Anaesthesiol Scand; 2014 May; 58(5):525-33. PubMed ID: 24580049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fibrinolyte therapy of septicemic shock in infancy and childhood].
    Mitterstieler G; Kurz R; Waltl H; Berger H
    Padiatr Padol; 1973; 8(2):225-31. PubMed ID: 4698436
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel biomarker-guided immunomodulatory approach for the therapy of sepsis.
    Trapnell BC
    Am J Respir Crit Care Med; 2009 Oct; 180(7):585-6. PubMed ID: 19762591
    [No Abstract]   [Full Text] [Related]  

  • 12. Toll-like receptor pathway signaling is differently regulated in neutrophils and peripheral mononuclear cells of patients with sepsis, severe sepsis, and septic shock.
    Koch A; Zacharowski K
    Crit Care Med; 2009 Jan; 37(1):346-7. PubMed ID: 19112297
    [No Abstract]   [Full Text] [Related]  

  • 13. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
    Baudo F; de Cataldo F
    Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
    Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
    Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [[Severe sepsis, inflammation and coagulation: a close connection between physiological anticoagulants and improved prognosis] ].
    De Gasperi A
    Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):1-2. PubMed ID: 11213541
    [No Abstract]   [Full Text] [Related]  

  • 16. Endothelial cell dysfunction and coagulation.
    Vallet B; Wiel E
    Crit Care Med; 2001 Jul; 29(7 Suppl):S36-41. PubMed ID: 11445732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should all septic patients be given systemic anticoagulation? No.
    van der Poll T; Opal SM
    Intensive Care Med; 2017 Mar; 43(3):455-457. PubMed ID: 28194511
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic approaches to innate immunity: severe sepsis and septic shock.
    Lolis E; Bucala R
    Nat Rev Drug Discov; 2003 Aug; 2(8):635-45. PubMed ID: 12904813
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of protein C concentrate in pediatric patients with sepsis.
    Silvani P; Camporesi A; Licari E; Wolfler A
    Minerva Anestesiol; 2005 Jun; 71(6):373-8. PubMed ID: 15886604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The response of antithrombin III activity after supplementation decreases in proportion to the severity of sepsis and liver dysfunction.
    Hayakawa M; Sawamura A; Yanagida Y; Sugano M; Hoshino H; Gando S
    Shock; 2008 Dec; 30(6):649-52. PubMed ID: 18496242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.